Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

(2011) William D. Travis et al.   Journal of Thoracic Oncology

Metformin Prevents Tobacco Carcinogen-Induced Lung Tumorigenesis

(2010) R. M. Memmott et al.   Cancer Prevention Research

Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer

(2010) Fusanori Yotsumoto et al.   CANCER SCIENCE

Insulin-like Growth Factor Receptor 1 (IGF1R) Gene Copy Number Is Associated With Survival in Operable Non–Small-Cell Lung Cancer: A Comparison Between IGF1R Fluorescent In Situ Hybridization, Protein Expression, and mRNA Expression

(2010) Rafal Dziadziuszko et al.   JOURNAL OF CLINICAL ONCOLOGY

Plasma Transforming Growth Factor α and Amphiregulin Protein Levels in NCIC Clinical Trials Group BR.21

(2010) Christina L. Addison et al.   JOURNAL OF CLINICAL ONCOLOGY

IFCT-0401 Trial: A Phase II Study of Gefitinib Administered as First-Line Treatment in Advanced Adenocarcinoma with Bronchioloalveolar Carcinoma Subtype

(2010) Jacques Cadranel et al.   Journal of Thoracic Oncology

Frequency of EGFR and KRAS Mutations in Japanese Patients with Lung Adenocarcinoma with Features of the Mucinous Subtype of Bronchioloalveolar Carcinoma

(2010) Akito Hata et al.   Journal of Thoracic Oncology

High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients

(2009) V. Ludovini et al.   ANNALS OF ONCOLOGY

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

(2009) Daniel D. Karp et al.   JOURNAL OF CLINICAL ONCOLOGY

Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib

(2009) Marie Wislez et al.   LUNG CANCER

Amphiregulin Promotes BAX Inhibition and Resistance to Gefitinib in Non-small-cell Lung Cancers

(2009) Benoît Busser et al.   MOLECULAR THERAPY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis

(2008) Noriko Motoi et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

The Role of Amphiregulin in Exemestane-Resistant Breast Cancer Cells: Evidence of an Autocrine Loop

(2008) X. Wang et al.   CANCER RESEARCH

Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers

(2008) K. Yonesaka et al.   CLINICAL CANCER RESEARCH

Amphiregulin Is a Promising Prognostic Marker for Liver Metastases of Colorectal Cancer

(2008) M. Yamada et al.   CLINICAL CANCER RESEARCH